Home > Rheumatology > EULAR 2022 > Late-Breaking Oral Abstracts > Sarilumab for polymyalgia rheumatica led to sustained remission and fewer flares

Sarilumab for polymyalgia rheumatica led to sustained remission and fewer flares

Presented By
Prof. Bhaskar Dasgupta , Anglia Ruskin University, United Kingdom
Conference
EULAR 2022
Trial
Phase 3, SAPHYR
Doi
https://doi.org/10.55788/c8512faf
Nearly 30% of participants receiving IL-6 inhibition in the randomised, phase 3 SAPHYR study achieved sustained remission. Furthermore, participants on sarilumab had a significant reduction of flares compared with those receiving placebo. Elevated IL-6 levels in polymyalgia rheumatica (PMR) have been linked to relapse and increased need for corticosteroids [1–3]. This led to the exploration of IL-6 inhibition with sarilumab as a potential therapeutic agent [1]. The phase 3, randomised, double-blind SAPHYR trial (NCT03600818) included patients with PMR ≥50 years who had at least 1 flare within 12 weeks before the trial while being on ≥7.5 mg of prednisolone. The study aimed to enrol 280 patients, but recruitment halted at 118 participants due to the COVID-19 pandemic. The participants were allocated to either placebo plus 52-week glucocorticoid tape...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on